Patent · US Active

Proteins binding NKG2D, CD16 and a tumor-associated antigen

US12378318B2 · kind B2 · utility

0Cited by

69References

11Claims

0Family size

Assignee

Dragonfly Therapeutics, Inc. · US

Inventors

Gregory P. Chang · Medford, US
Ann F. Cheung · Lincoln, US
Jinyan Du · Waltham, US
Daniel Fallon · Winchester, US
Asya Grinberg · Lexington, US
William Haney · Wayland, US
Bradley M. Lunde · Lebanon, US
Steven O'Neil · Wayland, US
Bianka Prinz · Lebanon, US
Ronnie Wei · Weston, US

Key dates

Filing date	Aug 8, 2019
Grant date	Aug 5, 2025
Priority date	—
Expiry date	Aug 6, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/94
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Multi-specific binding proteins that bind NKG2D receptor, CD 16, and a tumor-associated antigen selected from c-MET, KIT, F3, IGF1R, Lewis Y, MUC13, MUC4, MCAM, LRRC32, sialyl-Tn, gpA33, GD3, GM2, EPHA3, TNFRSF10A, TNFSF11, CD74, and PMEL are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.